
How Peptides Are Becoming Tools for the Future of Care Delivery
Despite conflicting opinions regarding safety, experts are exploring peptides for uses that run the gamut of patients’ clinical care.
With the US Department of Health and Human Services’ (HHS) recent action toward specific peptide formulations, pharmacists and prescribers may soon have more therapies to manage. However, whether prescribers and pharmacists believe these are transformative standards of care, or just possessing supplemental effects, is yet to be understood.
“I think more of these are going to be tools, and I think that’s the way most new medications are going to be considered anyways,” Matt Martin, PharmD, BCSCP, vice president of clinical services at PCCA, told Drug Topics®.
In part 2 of our interview with Martin, he was asked about the future potential behind peptides and their use in pharmacy practice. Despite rapid and ongoing speculation from the medical community, Martin believes these products, which are rather new to the general portion of society but not the medical industry, will certainly evolve in how they are used among providers and patient populations alike.
READ MORE:
Expanding Beyond Initial Regulatory Frameworks
Matt Martin highlighted that the regulatory environment is actively shifting, with the FDA’s Pharmacy Compounding Advisory Committee (PCAC) scheduled to evaluate 5 additional peptides by the end of February. Martin noted that positive advisory votes could expand the scope of federal compounding policies beyond the initial group of formulations.
This aligns directly with the official enforcement discretion policy issued by HHS under section 503A of the Federal Food, Drug, and Cosmetic Act.1
Under this interim framework signed by HHS leadership, federal regulators exercise enforcement discretion for state-licensed pharmacies compounding specific bulk drug substances including BPC-157, epitalon, KPV, MOTS-c, Semax, and TB-500, while formal rulemaking develops. Agency officials framed the initiative as a measure to expand patient access while curbing black-market proliferation through patient-specific prescriptions and quality testing requirements. However, legal challenges and state-level regulatory variances continue to create uncertainties for compounders and prescribers.1,2
Navigating Safety Data and Longevity Trends
As public interest in regenerative medicine and longevity grows, consumers increasingly look toward peptide therapies for anti-aging, recovery, and cognitive support. Market analysis shows that over 40% of consumers report a willingness to pursue advanced wellness solutions, propelled in part by the
Clinical experts emphasize that experimental peptides must not be viewed as shortcuts around core health practices such as sleep, nutrition, and metabolic monitoring. Unlike FDA-approved peptide drugs like insulin or semaglutide, many unapproved wellness peptides suffer from limited human trial data and present risks including injection site reactions, immune responses, and unknown drug interactions.
Regulatory notices explicitly state that interim compounding discretion does not constitute FDA approval or clinical safety validation, leaving clinicians to evaluate safety signals carefully and on their own.1,2
Pharmacists as Essential Guardians of Clinical Judgment
The rise of novel compounded therapies places pharmacists squarely in the middle of patient-centered care. One of Martin’s fellow colleagues, Sara Hover, RPh, FAARM, senior director of clinical services at PCCA, stressed during the NCPA Annual Convention that limited clinical trial data requires pharmacists to rely heavily on professional clinical judgment.4
By evaluating underlying drug mechanisms and individual safety profiles, pharmacists help prescribers determine the right therapy and dosage for specific patients who have exhausted conventional treatments. Balancing stringent regulatory compliance with patient care requires dedicated training and operational efficiency.
As Martin and other pharmacy leaders observe, peptides will serve as specialized clinical tools rather than universal standards of care, requiring careful oversight to integrate safely into future care delivery models.4
“Evidence is still developing. We still need to put more legs underneath the tables, but I think things are starting to grow,” concluded Hover in her conversation with Drug Topics. “Pharmacists really need to not only stay current but really we need to stay on the cutting edge so that we can help those patients, as many as possible.”
READ MORE:
REFERENCES
1. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. US Department of Health and Human Services. October 30, 2026. Accessed November 17, 2026. https://public-inspection.federalregister.gov/2026-22192.pdf
2. Steinzor P. 5 things to know about HHS's interim peptide compounding policy. AJMC. October 29, 2026. Accessed November 17, 2026. https://www.ajmc.com/view/5-things-to-know-about-hhs-s-interim-peptide-compounding-policy
3. Peptides are not a replacement for the basics: What will drive longevity in 2027? Eterna Wellness MD. Accessed November 17, 2026. https://eternawellnessmd.com/peptides-are-not-a-replacement-for-the-basics-what-will-drive-longevity-in-2027/
4. Nowosielski B, Hover S. Q&A: Emerging compounded therapies demand pharmacist’s clinical judgment | NCPA 2026. Drug Topics. October 15, 2026. Accessed November 17, 2026. https://www.drugtopics.com/view/emerging-compounded-therapies-demand-pharmacist-s-clinical-judgment-ncpa-2026
Related to this article







